ALLIANCE A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512.

Print this page

ALLIANCE A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512.

2.0 OBJECTIVES
2.1 Primary Objectives
2.1.1 To centrally genotype resected lung adenocarcinomas for EGFR mutations and ALK
rearrangements to facilitate accrual to randomized adjuvant studies.
2.1.2 To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from
peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow
clinically annotated advanced genomic analyses in concert with the NCI Center for Cancer
Genomics (CCG).
2.2 Secondary Objectives
2.2.1 To characterize the natural history of EGFR and ALK wild-type lung cancers to allow
subsequent development of targeted therapies against genotype-defined subpopulations in
the adjuvant and recurrent settings.
2.2.2 To cross-validate local genotyping assays for EGFR and ALK with a central reference
standard.
2.3 Exploratory/Other Objectives
2.3.1 To study the genomic evolution of lung cancers by comparing genomic characteristics at
resection and at recurrence.

Protocol Number: 031504
Phase: NA
Applicable Disease Sites: Lung
Drugs Involved:
Principal Investigator: Joseph Aisner
Research Nurse: Michelle Orlick
Scope: National
Therapies Involved:
Participating Institutions: Rutgers Cancer Institute of New Jersey
Jersey Shore University Medical Center
Riverview Medical Center
Robert Wood Johnson University Hospital Somerset

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@cinj.rutgers.edu.

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health